查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1891797

全球子宮肌瘤治療市場：依產品類型、介紹、應用、技術/作用機制、最終用戶和地區分析—市場規模、行業趨勢、機會分析和預測（2026-2035 年）

Global Uterine Fibroid Drugs Market: Analysis By Product Type, Deployment, Application, Technology/Mode of Action, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

子宮肌瘤治療市場目前正經歷強勁成長，預計到 2025 年將達到約 38 億美元。預測顯示，這一顯著成長趨勢將在未來十年持續，到 2035 年將達到驚人的 128 億美元。 2026 年至 2035 年的複合年增長率 (CAGR) 為 14.4%，證實了全球對有效子宮肌瘤治療方法日益增長的需求和重要性。

推動市場快速成長的關鍵因素很多。其中一個主要驅動因素是子宮肌瘤盛行率的不斷上升，這與飲食、肥胖和環境因素等多種生活方式因素有關。隨著人們對子宮肌瘤的認識不斷提高，診斷技術的進步也使得越來越多的女性被診斷出患有此病，從而擴大了尋求治療的潛在患者群體。除了盛行率的上升，患者的治療選擇也發生了顯著變化，轉向非手術、保留生育功能的療法。

市場趨勢

子宮肌瘤治療市場的主要參與者包括艾伯維 (AbbVie)、輝瑞 (Pfizer)、Myovant Sciences、Hologic、波士頓科學 (Boston Scientific)、美敦力 (Medtronic) 和 Insightec 等大型製藥和醫療器械公司。這些公司策略性地專注於多方面治療方案，將荷爾蒙療法和促性腺激素釋放激素 (GnRH) 拮抗劑與先進的醫療器材相結合，以提供全面的治療解決方案。這種方法旨在透過提供藥物和手術治療方案來滿足患者的多樣化需求。

在眾多知名公司中，住友製藥展現了強勁的財務業績和韌性。根據2025年10月發布的修訂預測，住友製藥預計2025財年銷售額將達到4,290億日圓。該公司還預計截至2025年3月的財年營業利潤將達到288億日元，顯示其正處於復甦和財務穩定的階段。

2025年10月，Apotex宣布獲得治療子宮肌瘤的藥物Linzagolix在加拿大的獨家銷售權，這是一項重大進展。此舉顯示Apotex對女性健康的堅定承諾，並擴大了在加拿大子宮肌瘤治療市場的佔有率。 Linzagolix已在歐盟和日本獲得批准，證實了其治療潛力和監管認可。

同時，艾伯維的藥品組合也持續穩定發展。公司預計到 2027 年，其兩大免疫學產品線的合併銷售額將超過 270 億美元。這一強勁的收入來源間接支持了艾伯維的研發預算，使其能夠持續投資於女性健康領域，包括子宮肌瘤治療。艾伯維雄厚的財務實力和多元化的產品線使其能夠繼續保持其在子宮肌瘤治療市場的領先地位。

核心成長驅動因子

子宮肌瘤在全球的發生率極高，是最常見的婦科疾病之一。這種廣泛的發病率對子宮肌瘤治療市場產生了重大影響，並推動了對有效治療方案的需求。根據流行病學數據（與美國疾病管制與預防中心 (CDC) 的估計一致），光是在美國，就有約 2,600 萬名 15 至 50 歲的女性患有子宮肌瘤。這驚人的數字凸顯了該疾病對相對年輕的育齡人群帶來的沉重醫療負擔。

新興機會

引進替代療法以減輕骨密度流失，代表子宮肌瘤治療市場的重要機會和成長趨勢。許多用於治療子宮肌瘤的荷爾蒙療法，特別是促性腺激素釋放激素 (GnRH) 拮抗劑和激動劑，會因抑制雌激素而導致骨密度流失。這種骨密度流失會對患者造成嚴重風險，可能導致骨質疏鬆和骨折，並限制了這些有效療法的長期應用。將低劑量雌激素和黃體素與主要治療相結合的替代療法的開發和引入，旨在抵消這種副作用，同時又不影響子宮肌瘤的治療效果。

優化障礙

高昂的每月零售價格對患者就醫構成重大障礙，並可能嚴重阻礙子宮肌瘤治療市場的成長。儘管創新療法和先進藥物提供了有前景的治療選擇，但其高昂的費用往往使許多患者難以負擔，尤其是那些沒有全面保險或經濟資源不足的患者。這種經濟負擔能力的挑戰限制了更廣泛患者群體獲得這些療法的機會，最終阻礙了市場擴張和普及。這些藥物的高昂費用迫使患者做出艱難的抉擇，有時甚至因為經濟原因不得不延後或停止治療。

目錄

第一章：摘要整理：全球子宮肌瘤治療市場

第二章：研究方法與架構

  • 研究目標
  • 產品概述
  • 市場區隔
  • 質性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 依地區劃分的原始調查受訪者
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第三章 全球子宮肌瘤治療藥品市場概況

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入預測（2020-2035）
    • 價格趨勢分析
  • 市場吸引力分析
    • 依細分市場/地理劃分
    • 可操作的洞見（分析師）建議）

第四章 競爭格局概覽

  • 市場集中度
  • 公司市佔率分析（價值，2025 年）
  • 競爭格局分析與基準分析

第五章：全球子宮肌瘤治療市場分析

  • 市場動態與趨勢
    • 成長驅動因素
    • 限制因素
    • 機遇
    • 主要趨勢
  • 市場規模及預測（2020-2035 年）
    • 依實作類型
    • 依產品類型
    • 依技術/作用機制
    • 依應用
    • 依最終用戶
    • 依區域

第六章：北美子宮肌瘤治療市場分析

第七章：歐洲子宮肌瘤治療市場分析

第八章：亞太地區子宮肌瘤治療市場分析

第九章：中東及非洲子宮肌瘤治療市場分析

第十章：南美洲子宮肌瘤治療市場分析

第十一章：公司簡介

  • 艾伯維公司 (AbbVie Inc.)
  • 大元製藥株式會社 (Daewon Pharmaceutical Co., Ltd.)
  • 住友製藥株式會社 (Sumitomo Pharma Co., Ltd.)
  • 輝瑞公司 (Pfizer Inc.)
  • 吉賽藥株式會社 (Kissei Pharmaceutical Co.,)有限公司
  • Neurocrine Biosciences, Inc.
  • 天元生物科技股份有限公司
  • ObsEva SA
  • 其他傑出球員

第 12 章：附錄

簡介目錄
Product Code: AA12251605

The Uterine Fibroid Drugs Market is currently undergoing robust expansion, with its valuation reaching approximately US$ 3.8 billion in 2025. Projections indicate that this significant growth trajectory will continue over the coming decade, with the market expected to reach an impressive valuation of US$ 12.8 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 14.4% during the forecast period from 2026 to 2035, underscoring the increasing importance and demand for effective uterine fibroid treatments worldwide.

Several key factors are driving this rapid market growth. One of the primary contributors is the rising prevalence of uterine fibroids, which has been linked to various lifestyle factors such as dietary habits, obesity, and environmental influences. As awareness of fibroids increases and diagnostic capabilities improve, more women are being identified with this condition, thereby expanding the potential patient pool seeking treatment. In addition to the growing prevalence, there is a marked shift in patient preferences toward non-surgical and fertility-preserving treatment options.

Noteworthy Market Developments

Key players in the uterine fibroid drugs market include major pharmaceutical and medical device companies such as AbbVie, Pfizer, Myovant Sciences, Hologic, Boston Scientific, Medtronic, and Insightec. These companies are strategically focusing on a multifaceted approach that combines hormonal therapies and Gonadotropin-Releasing Hormone (GnRH) antagonists with the integration of advanced medical devices to offer comprehensive treatment solutions. This approach aims to address the diverse needs of patients by providing both pharmacological and procedural options.

Among the notable companies, Sumitomo Pharma has demonstrated strong financial performance and resilience. Based on the revised forecast released in October 2025, Sumitomo Pharma projects its fiscal year 2025 revenue to reach JPY 429 billion. The company also anticipates an operating profit of JPY 28.8 billion for the fiscal year ending March 2025, signaling a phase of recovery and financial stability.

In a significant development during October 2025, Apotex announced the acquisition of exclusive Canadian rights to linzagolix, a drug used for the treatment of uterine fibroids. This move underscores Apotex's strengthened commitment to women's health and expands its presence in the uterine fibroid market within Canada. Linzagolix has already received approval in the European Union and Japan, affirming its therapeutic potential and regulatory acceptance.

Meanwhile, AbbVie continues to make significant strides in its broader pharmaceutical portfolio. The company expects its combined sales from its immunology product duo to exceed US$ 27 billion by 2027. This robust revenue stream indirectly supports AbbVie's research and development budget, enabling continued investment in women's health assets, including uterine fibroid therapies. AbbVie's financial strength and diversified pipeline position it well to maintain leadership in the uterine fibroid drugs market

Core Growth Drivers

The prevalence of uterine fibroids is exceptionally high on a global scale, establishing it as one of the most common gynecological conditions worldwide. This widespread occurrence significantly influences the uterine fibroid drugs market, driving demand for effective treatment options. Epidemiological data, consistent with estimates from the Centers for Disease Control and Prevention (CDC), reveal that approximately 26 million women in the United States alone, aged between 15 and 50, are affected by uterine fibroids. This staggering figure underscores the substantial healthcare burden posed by the condition within a relatively young and reproductive-age population.

Emerging Opportunity Trends

The integration of add-back therapy to mitigate bone density loss represents a significant opportunity and a growing trend within the uterine fibroid drugs market. Many of the hormonal treatments used to manage uterine fibroids, particularly Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists, can lead to decreased bone mineral density as a side effect due to the suppression of estrogen. This reduction in bone density poses a serious risk for patients, potentially leading to osteoporosis and fractures, which has historically limited the long-term use of these effective therapies. The development and incorporation of add-back therapy-where low doses of estrogen and progestin are administered alongside the primary treatment-aim to counteract this side effect without diminishing the efficacy of fibroid management.

Barriers to Optimization

High monthly retail pricing presents a considerable barrier to patient access, which could significantly hamper the growth of the uterine fibroid drugs market. While innovative therapies and advanced medications offer promising treatment options, their elevated costs often place them out of reach for many patients, particularly those without comprehensive insurance coverage or adequate financial resources. This pricing challenge limits the ability of a broad patient population to benefit from these treatments, thereby restricting market expansion and adoption rates. The high cost of these drugs can lead to difficult choices for patients, forcing some to delay or forgo treatment altogether due to affordability concerns.

Detailed Market Segmentation

By Product Type, the Gonadotropin-Releasing Hormone (GnRH) antagonists have swiftly secured a dominant 33.5% market share as of 2025. This notable surge reflects a shift in treatment preferences, as these oral antagonists offer a highly attractive alternative to traditional surgical interventions. The growing adoption of these drugs underscores the market's evolving landscape, where patients and healthcare providers alike are seeking effective, non-invasive options that can manage uterine fibroids with fewer risks and greater convenience.

By Deployment, Hospitals and specialized clinical settings dominate the uterine fibroid drugs market in terms of revenue generation, accounting for a remarkable 54.36% of the total market share. This substantial figure is largely driven by the common practice of bundling pharmacotherapy with costly surgical procedures, which elevates the overall treatment expenditure within these healthcare environments. In many cases, patients receiving drug therapies for uterine fibroids in hospitals or specialized clinics are also undergoing surgical interventions such as myomectomy or uterine artery embolization, resulting in a combined treatment approach that significantly increases revenue streams from these settings.

By Technology, Hormonal modulation technologies hold the dominant position within the uterine fibroid drugs market, securing the highest market share of 44.25%. This leading share is primarily attributed to the effectiveness of these therapies in directly targeting the estrogen and progesterone receptors that play a critical role in driving tumor proliferation. Uterine fibroids are hormone-sensitive tumors, and the growth of these benign tumors is closely linked to the presence and activity of these sex hormones. By modulating hormone levels or blocking their receptors, hormonal therapies can effectively slow down or even reverse fibroid growth.

By Application, Symptomatic treatment strategies, particularly those focusing on managing heavy menstrual bleeding (HMB), dominate the uterine fibroid drugs market, accounting for a substantial 49.46% share. This significant market presence is largely because heavy menstrual bleeding is one of the most debilitating and commonly reported symptoms experienced by women suffering from uterine fibroids. The severity and impact of HMB on patients' quality of life drive strong demand for effective therapeutic options that can alleviate this distressing condition.

Segment Breakdown

By Deployment Type

  • Hospital/Clinic-Based Prescriptions
  • Retail Pharmacy/Drug Stores
  • Online/E-pharmacy

By Product Type

  • GnRH Agonists & Antagonists
  • Leuprolide
  • Relugolix
  • Selective Progesterone Receptor Modulators
  • Ulipristal acetate
  • Vilaprisan
  • Hormonal Therapies
  • Combined oral contraceptives
  • Progestins
  • Nonsteroidal Anti-Inflammatory Drugs
  • Ibuprofen
  • Naproxen
  • Other Adjunctive Therapies
  • Iron supplements
  • Herbal/OTC remedies

By Technology/Mode of Action

  • Hormonal Modulation
  • GnRH Receptor Targeting
  • Anti-inflammatory Mechanisms
  • Progesterone Receptor Modulation

By Application

  • Symptomatic Treatment
  • Fertility & Reproductive Health
  • Pre-Surgical Management
  • Post-Surgical Therapy
  • Other Applications

By End-User

  • Hospitals & Specialty Clinics
  • Gynecology & Women's Health Centers
  • Retail Pharmacies
  • E-pharmacies/Online Platforms
  • Other End-Users

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America is notably influenced by the aggressive pricing strategies employed for proprietary oral GnRH antagonists, which have enabled the region to capture a commanding market share of approximately 34.50%. Unlike markets where revenue is driven primarily by patient volume, the financial dynamics in North America-particularly in the United States-are shaped more significantly by a "willingness to pay" model. This approach reflects the unique structure of the US healthcare system, where pricing power and reimbursement mechanisms play a critical role in determining market success for pharmaceutical products.
  • In this context, the high prices commanded by proprietary oral GnRH antagonists have contributed substantially to revenue generation, despite the relatively stable or moderate patient base. These drugs, often positioned as premium treatment options, benefit from strong payer support and patient access programs that reflect the prioritization of innovative therapies in the region. The ability of pharmaceutical companies to negotiate favorable pricing and reimbursement terms has shifted the economic landscape of the uterine fibroid drugs market, emphasizing value-based care and willingness to invest in advanced treatments.

Leading Market Participants

  • AbbVie Inc.
  • Daewon Pharmaceutical Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Pfizer Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • TiumBio Co., Ltd.
  • ObsEva SA
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Uterine Fibroid Drugs Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Uterine Fibroid Drugs Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Material Provider
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. End User
  • 3.2. Industry Outlook
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Segment/Region
    • 3.6.2. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Uterine Fibroid Drugs Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Deployment Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Hospital/Clinic-Based Prescriptions
        • 5.2.1.1.2. Retail Pharmacy/Drug Stores
        • 5.2.1.1.3. Online/E-pharmacy
    • 5.2.2. By Product Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. GnRH Agonists & Antagonists
          • 5.2.2.1.1.1. Leuprolide
          • 5.2.2.1.1.2. Relugolix
        • 5.2.2.1.2. Selective Progesterone Receptor Modulators
          • 5.2.2.1.2.1. Ulipristal acetate
          • 5.2.2.1.2.2. Vilaprisan
        • 5.2.2.1.3. Hormonal Therapies
          • 5.2.2.1.3.1. Combined oral contraceptives
          • 5.2.2.1.3.2. Progestins
        • 5.2.2.1.4. Nonsteroidal Anti-Inflammatory Drugs
          • 5.2.2.1.4.1. Ibuprofen
          • 5.2.2.1.4.2. Naproxen
        • 5.2.2.1.5. Other Adjunctive Therapies
          • 5.2.2.1.5.1. Iron supplements
          • 5.2.2.1.5.2. Herbal/OTC remedies
    • 5.2.3. By Technology/Mode of Action
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hormonal Modulation
        • 5.2.3.1.2. GnRH Receptor Targeting
        • 5.2.3.1.3. Anti-inflammatory Mechanisms
        • 5.2.3.1.4. Progesterone Receptor Modulation
    • 5.2.4. By Application
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Symptomatic Treatment
        • 5.2.4.1.2. Fertility & Reproductive Health
        • 5.2.4.1.3. Pre-Surgical Management
        • 5.2.4.1.4. Post-Surgical Therapy
        • 5.2.4.1.5. Other Applications
    • 5.2.5. By End-User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospitals & Specialty Clinics
        • 5.2.5.1.2. Gynecology & Women's Health Centers
        • 5.2.5.1.3. Retail Pharmacies
        • 5.2.5.1.4. E-pharmacies/Online Platforms
        • 5.2.5.1.5. Other End-Users
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
  • 5.2.6.1.2.1.1. The UK
  • 5.2.6.1.2.1.2. Germany
  • 5.2.6.1.2.1.3. France
  • 5.2.6.1.2.1.4. Italy
  • 5.2.6.1.2.1.5. Spain
  • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
  • 5.2.6.1.2.2.1. Poland
  • 5.2.6.1.2.2.2. Russia
  • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. South Korea
          • 5.2.6.1.3.5. Australia & New Zealand
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa
          • 5.2.6.1.4.1. UAE
          • 5.2.6.1.4.2. Saudi Arabia
          • 5.2.6.1.4.3. South Africa
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Uterine Fibroid Drugs Market Analysis

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Deployment Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technology/Mode of Action
    • 6.2.4. By Application
    • 6.2.5. By End-User
    • 6.2.6. By Country

Chapter 7. Europe Uterine Fibroid Drugs Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Deployment Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technology/Mode of Action
    • 7.2.4. By Application
    • 7.2.5. By End-User
    • 7.2.6. By Country

Chapter 8. Asia Pacific Uterine Fibroid Drugs Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Deployment Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technology/Mode of Action
    • 8.2.4. By Application
    • 8.2.5. By End-User
    • 8.2.6. By Country

Chapter 9. Middle East & Africa Uterine Fibroid Drugs Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Deployment Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technology/Mode of Action
    • 9.2.4. By Application
    • 9.2.5. By End-User
    • 9.2.6. By Country

Chapter 10. South America Uterine Fibroid Drugs Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Deployment Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technology/Mode of Action
    • 10.2.4. By Application
    • 10.2.5. By End-User
    • 10.2.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Daewon Pharmaceutical Co., Ltd.
  • 11.3. Sumitomo Pharma Co., Ltd.
  • 11.4. Pfizer Inc.
  • 11.5. Kissei Pharmaceutical Co., Ltd.
  • 11.6. Neurocrine Biosciences, Inc.
  • 11.7. TiumBio Co., Ltd.
  • 11.8. ObsEva SA
  • 11.9. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators